01 The approach
Two diseases. One axis.
Metabolic and neural disease share a biology that fragmented tools keep apart. Sleep is the one window where they converge — and where a single platform can read both at once.
02 The platform
One signal, read across drug development.
A night of sleep, decoded into quantitative biomarkers — deployed at every stage where a CNS or metabolic program lives or dies.
/01
Stratify
Characterize patients and surface disease mechanism from sleep physiology — before enrollment.
/02
Prove
Show target engagement and read treatment response early, with quantitative endpoints that lift success.
/03
Expand
Strengthen efficacy evidence and generate the real-world signal that supports new indications.
Reading the brain before the disease declares itself.